Experienced business leader, advisor, and investor Brian Frenzel holds a Bachelor of Science in Physics from Stanford University and a Master of Business Administration from the Stanford Graduate School of Business. This education laid the foundation for his success in co-founding four medical products companies in the 1980s and 1990s and participation in a variety of angel investor and community service groups over a career spanning three decades.
Brian Frenzel has committed himself to building businesses that develop new technologies and products to treat a large number of serious medical conditions, including infectious diseases such as HIV/AIDS and hepatitis C, reproductive disorders such as preterm labor and dysfunctional uterine bleeding, autoimmune diseases such as rheumatoid arthritis and psoriasis, and neurodegenerative diseases such as stroke, Parkinson’s, and Alzheimer’s.
Drawing on a wealth of experience, Mr. Frenzel serves as the President and Chief Executive Officer of Tosk, Inc., a company specializing in the discovery and development of new drugs to block the adverse and potentially life-threatening side effects of chemotherapeutic drugs and radiation therapies for the treatment of cancer. In addition to improving the quality of life for patients, these drugs have the potential to improve the efficacy of chemotherapeutic agents by allowing for increased dosing over longer periods. Brian Frenzel is a co-inventor of Tosk’s first products for mucositis and cardiotoxicity side-effect reduction. Neurological diseases and disorders comprise another area in which Brian Frenzel seeks improved treatments and outcomes for patients.
Mr. Frenzel serves as the Director at SanBio, Inc., a cell therapy company whose primary focus is to reverse nerve damage and restore function for disabled stroke victims. The technology, based upon activated bone marrow stem cells, has also shown promise in the treatment of Parkinson’s disease, multiple sclerosis, traumatic brain injury, retinal disorders, and spinal cord injury. A third company for which Brian Frenzel serves as an advisor is Trigemina, Inc., which is developing new products for pain relief with first targets being trigeminal neuralgia, migraine headache, and post-surgical pain. All three companies have products in early-stage clinical studies and, in aggregate, have the potential to improve outcomes and save the lives of millions of patients worldwide.